Voyager-V1 + cemiplimab

Voyager-V1 + cemiplimab is an investigational combination immunotherapy consisting of Voyager-V1 (VV1), an engineered oncolytic vesicular stomatitis virus (VSV), and cemiplimab (Libtayo), a fully human monoclonal antibody targeting the programmed cell death protein 1 (PD-1) immune checkpoint. Voyager-V1 is genetically modified to express human interferon beta (IFNβ) to enhance tumor selectivity and stimulate anti-tumor immune responses, as well as the thyroidal sodium iodide symporter (NIS) to enable noninvasive imaging of viral replication and spread. Cemiplimab acts by blocking the interaction of PD-1 with its ligands, PD-L1 and PD-L2, thereby restoring T-cell mediated anti-tumor activity. The combination is designed to synergistically enhance anti-tumor efficacy by using the oncolytic virus to infect and lyse tumor cells, inflame the tumor microenvironment, and recruit immune cells, while cemiplimab prevents T-cell exhaustion. Developed under a strategic collaboration between Vyriad and Regeneron Pharmaceuticals, the combination is currently being evaluated in Phase 2 clinical trials for various advanced solid tumors, including melanoma, head and neck squamous cell carcinoma, and colorectal cancer.

Other names

VSV-IFNbeta-NIS + cemiplimabVSV-IFNβ-NIS + cemiplimabVoyager V1 + cemiplimabVoyager-V1 + LibtayoVV1 + cemiplimabVV1 + Libtayo